Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
Recbio's Novel Adjuvanted Shingles Vaccine Accepted for Clinical Trial in China
Jiangsu Recbio Technology Co., Ltd. is excited to announce that their research project has achieved a significant milestone. The National Medical Products Administration (NMPA) has accepted the Company's clinical trial application for their innovative adjuvanted recombinant shingles vaccine, REC610. ...
MyoPax's breakthrough regenerative cell product for Exstrophy-Epispadias Complex earns Rare Pediatric Disease Designation
The U.S. Food and Drug Administration (FDA) has granted MyoPax, a young European biotech start-up, a Rare Pediatric Disease Designation (RPDD) for their innovative regenerative cell therapies. MyoPax focuses on developing treatments for debilitating muscle disorders...
FDA Approves Skyline Therapeutics' Novel Gene Therapy for Macular Degeneration
Skyline Therapeutics, a company focused on developing solutions for rare and severe diseases, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application....
Janssen's Novel Oral IL-23 Receptor Antagonist Shows Positive Results for Plaque Psoriasis
The Janssen Pharmaceutical Companies of Johnson & Johnson have released positive topline results from a Phase 2b clinical trial called FRONTIER 1. The trial evaluated the efficacy of a novel oral interleukin-23 receptor (IL-23R) antagonist peptide called JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis (PsO)....
FDA Approves Novel Alzheimer's disease Treatment through Traditional Pathway
The U.S. Food and Drug Administration (FDA) has converted Leqembi (lecanemab-irmb), a treatment for adult patients with Alzheimer's disease, to traditional approval. This decision was made after a confirmatory trial validated its clinical benefit...
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for NRG1+ pancreatic cancer treatment
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in the development of innovative antibodies for cancer treatment, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for their drug zenocutuzumab (Zeno)....
Ascendia Pharmaceuticals' Nanoemulsion IV Formulation for Clopidogrel Granted IND Approval
Ascendia Pharmaceuticals' has announced a significant achievement in the development of a novel nanoemulsion IV formulation for clopidogrel. This innovative formulation, utilizing Ascendia's patented EmulSol® nanotechnology, has received Investigational New Drug (IND) approval from the FDA. The partnership between Ascendia Pharmaceuticals and AcuteBio, LLC has played a crucial role in the formulation's success...
Breakthrough Therapy Designation Granted to Precigen's PRGN-2012 AdenoVerse™ Immunotherapy
Precigen, Inc. (Nasdaq: PGEN) has announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to their investigational PRGN-2012 AdenoVerse immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). This designation expedites the development and review of medicines that target serious or life-threatening diseases and demonstrate significant improvement over existing therapies....
Aardvark Therapeutics Receives FDA Orphan Drug Designation for ARD-101 in Prader-Willi Syndrome
Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company, has announced that its lead program, ARD-101, has received Orphan Drug Designation from the FDA. ARD-101 is an oral small molecule bitter taste receptor (TAS2R) agonist that shows potential in addressing the challenges...
Kymera Therapeutics' KT-253 Granted FDA Orphan Drug Designation Novel and Selective MDM2 Degrader for AML Treatment
Kymera Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to their drug candidate, KT-253, for the treatment of Acute Myeloid Leukemia (AML). KT-253 is a highly potent and selective MDM2 degrader that specifically targets MDM2, a crucial regulator of the tumor suppressor protein p53....
